Novartis lowered expectations for an experimental diabetes compound Galvus but submitted a bone and a cancer drug to regulators ahead of schedule. Galvus (vildagliptin), a once-daily oral treatment ...

Type 2 diabetes already affects 230 million people and is rising at epidemic levels with a worldwide prevalence of 350 million forecast for 2025. The global population is getting progressively older ...

Novartis said Monday that the FDA has requested additional data on the drugmaker’s experimental diabetes treatment Galvus, potentially delaying launch of the drug for up to a year and helping Merck’s ...

Novartis Committed to Making Galvus Available for Patients with Type 2 Diabetes After US Regulators Issue "Approvable Letter" An "approvable letter" means the FDA is prepared to approve an ...

Novartis is presenting data at the American Diabetes Association's (ADA) 72nd Scientific Sessions in Philadelphia, USA that demonstrate the safety and efficacy profile of Galvus® (vildagliptin) in ...

The future of Novartis diabetes drug Galvus across the Atlantic looks very uncertain indeed, after the group’s chief executive Dan Vasella said the agent might not be re-filed with US regulators. The ...

For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website is to provide initial guidance only and it does ...

ZURICH, Nov 6 (Reuters) - Swiss drugmaker Novartis AG has proposed changes to European prescribing information for its Galvus diabetes medicine, after finding safety problems with higher doses.

New data presented at the European Association for the Study of Diabetes meeting in Rome, prove for the first time how Novartis’ oral dipeptidyl peptidase 4 (DPP-4) inhibitor for type 2 diabetes, ...